HALLE/SAALE, Germany, June 19, 2014 – Probiodrug AG (Probiodrug), today announced that Dr. Hendrik Liebers, Probiodrug’s chief financial officer, will present a corporate update at the annual BIO International Convention, being held from the 23rd to the 26th of June 2014. Dr. Lieber’s presentation will take place at 11:15am on the 26th of June in the Pacific Beach Room at the San Diego Convention Center.
The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. For more information on BIO and the BIO International Convention, please visit convention.bio.org.
Probiodrug is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions to treat people with Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of glutaminyl cyclase, providing the Company with a dominant position in this field of research. Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors.
Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Probiodrug was founded in 1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund. For more information, please visit www.probiodrug.de.
Dr. Konrad Glund, CEO
Tel: +49 (345) 555-9900